Robert Thomas Dechant - Dec 31, 2022 Form 3 Insider Report for IBEX Ltd (IBEX)

Role
Chief Executive Officer, Director
Signature
/s/ Lisa Lenstrohm, Attorney-in-Fact
Stock symbol
IBEX
Transactions as of
Dec 31, 2022
Transactions value $
$0
Form type
3
Date filed
6/30/2023, 04:12 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IBEX Common Shares 206K Dec 31, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IBEX Stock Option (Right to Buy Common Shares) Dec 31, 2022 Common Shares 50K $12.75 Direct F2
holding IBEX Stock Option (Right to Buy Common Shares) Dec 31, 2022 Common Shares 45K $19.00 Direct F2
holding IBEX Stock Option (Right to Buy Common Shares) Dec 31, 2022 Common Shares 20K $19.85 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes (i) 932 restricted stock units ("RSUs") that vest on July 1, 2023 and (ii) 968 RSUs that vest on August 1, 2023, all subject to continued employment.
F2 The shares subject to this option are fully vested and exercisable.
F3 Performance stock units ("PSUs") granted on December 14, 2020. Each PSU represents a contingent right to receive one share of the Company's common shares. The PSUs vest upon the Company's common shares achieving a specified price per share over a 30 day period.

Remarks:

The Company determined that as of December 31, 2022, the Company no longer qualified as a foreign private issuer. Beginning July 1, 2023, the Reporting Person is subject to Section 16 of the Securities Exchange Act of 1934. Exhibit 24 - Power of Attorney